Although corneal transplantation (Tx) is readily available in the United States and certain other regions of the developed world, the need for human donor corneas worldwide far exceeds supply. There is currently renewed interest in the possibility of using corneas from other species, especially pigs, for Tx into humans (xeno-Tx). The biomechanical properties of human and pig corneas are similar. Studies in animal models of corneal xeno-Tx have documented both humoral and cellular immune responses that play roles in xenograft rejection. The results obtained from the Tx of corneas from wild-type (ie, genetically unmodified) pigs into nonhuman primates have been surprisingly good and encouraging. Recent progress in the genetic manipulation of pigs has led to the prospect that the remaining immunological barriers will be overcome. There is every reason for optimism that corneal xeno-Tx will become a clinical reality within the next few years.
C linical corneal transplantation (Tx) enjoys considerable success (Table 1) , particularly in uncomplicated patients with nonvascularized native corneas. [1] [2] [3] However, in high-risk patients with inflamed and/or vascularized corneas, the survival rate is lower, even with topical and/or systemic immunosuppression ( Table 1) . 2 Although corneal Tx is readily available in the United States and in certain other regions of the developed world, the worldwide need for human donor corneas far exceeds supply ( Table 2 ). In some parts of Asia, especially China, Korea, and Japan, where cultural and religious concerns make it difficult to obtain corneas from human cadavers, severe shortages of donor corneas persist. 4 In some parts of the world, the pig as a source of corneas may be unacceptable on religious grounds (eg, Islam, Judaism, and Jainism). However, beliefs often vary within religious groups or on an individual basis. Furthermore, for example, although the prohibition of pork for consumption is mentioned in the Holy Quran, there is no definitive comment on the use of pig tissues or organs for therapeutic purposes. Discussion with representatives of these religious groups will be required to enable guidelines to be drawn up.
In addition, the availability of corneas can change over time. For example, although there was no shortage in the past in South Africa (799 donated corneas in 2005), there has been significantly decreased availability recently (330 in 2008), largely because of the high incidence of infectious diseases in potential donors, particularly human immunodeficiency virus. Even in the developed world, the increasing popularity of refractive surgery will reduce the supply of human corneas 5, 6 ; current Eye Bank Association of America standards do not allow the use of corneas that have been subjected to surgery for penetrating keratoplasty, although they can be used for tectonic grafting and posterior lamellar procedures.
THE POTENTIAL OF CORNEAL XENO-TX
In addressing this shortage, animal corneas might prove acceptable substitutes. Xeno-Tx, using pigs as the source animal, offers the potential of an unlimited number of organs, tissues, and cells for Tx into humans. 7, 8 There are many similarities between pigs and humans in regard to anatomy and physiology [9] [10] [11] (Table 3 and Fig. 1 ). Ethically, pigs represent an acceptable choice as an alternative source of organs for humans. 12, 13 Immunologically, however, the pig is less desirable than the nonhuman primate as a source because of the genetic distance between pigs and humans. However, because the cornea is an immune-privileged tissue and is not immediately vascularized, its fate as a xenograft is likely to be better than that of organ xenografts. 7, 14 Furthermore, advances in the genetic engineering of pigs are steadily enabling their tissues to become resistant to injury from the primate immune response. 7, 8 Indeed, selected genetic modifications to the source pig may render the cornea comparable, or even superior, to a human cornea with regard to its ability to resist rejection, even in the absence of local steroid therapy.
Pigs can be bred, housed, and closely monitored in a ''clean'' environment, which would prevent the risk of transfer of potentially infectious agents with the cornea. The potential risk of transfer of porcine endogenous retroviruses to the recipient, and possibly to the recipient's contacts, [15] [16] [17] is now believed to be very small and acceptable if the potential benefits to the recipient are anticipated to be considerable. 18 The special housing required for the pigs to be used for clinical purposes could be provided in a small number of facilities in developed countries, and the corneas mailed to wherever required, including less well-developed countries. Unlike deceased human corneas, pig corneas would be known to be definitively free of pathogenic microorganisms.
CLINICAL EXPERIENCE WITH CORNEAL XENO-TX
There have been several attempts to use animal corneas for Tx in humans, beginning in the early 19th century. 19 These have involved corneas from pigs, sheep, dogs, and rabbits [20] [21] [22] [23] [24] and in the 20th century, from gibbons, cows, and fish. [25] [26] [27] The first clinical corneal xeno-Tx (in 1838) was performed by Kissam, 20 more than half a century before the first corneal allo-Tx, which was carried out by Zirm in 1905. [28] [29] [30] Although several xenotransplants were reported to be technically successful, most of the xenografts from widely disparate species were rejected within 1 month.
Although the results of the Tx of the corneas from gibbons were encouraging (50% of the corneas remained transparent for .5 months), 25 the use of nonhuman primates as sources of grafts for human recipients has largely been excluded. 12, 13 Nonhuman primates exhibit limited reproductive capacity and availability and because of the potential risk of transfer of viruses, for example, those related to the human immunodeficiency virus family, present a possible health risk to human recipients. Furthermore, the use of species with many behavioral similarities to humans would be ethically unacceptable to a segment of society.
EXPERIMENTAL CORNEAL XENO-TX IN NONHUMAN PRIMATES
There is an extensive literature on experimental corneal xeno-Tx in both large and small animal models. However, there have been very few recent studies in the clinically relevant pig-to-nonhuman primate Tx model. Pan et al 31 carried out a study of wild-type (that is, unmodified, WT) pig corneal transplants in rhesus monkeys. They reported that grafts in untreated (nonimmunosuppressed) monkeys were rejected within 15 days, although hyperacute rejection was not seen. The rejected xenografts showed inflammatory cell infiltrates in the anterior part of the stroma and absent or abnormal endothelium, which suggested that corneal endothelium may be a major target for immune factors, such as antibodies or complement in the aqueous humor or cells such as T cells and macrophages. Remarkably, subconjunctival injections of a corticosteroid (betamethasone) every 10 days for 3 months prolonged survival for several months. The authors did not investigate antibody deposition on the graft or serum levels of antipig antibodies after rejection. This result, if confirmed, is very encouraging for the use of pig corneas in clinical practice. However, it would be ideal if corneal xeno-Tx did not require prolonged immunosuppressive therapy of any sort. The Tx of corneas from genetically modified pigs might enable this goal to be achieved.
THE IMMUNE RESPONSE TO CORNEAL XENOGRAFTS
The mechanisms of rejection of a corneal xenograft are significantly different from those of a vascularized organ xenograft. 32 The immune-privileged environment of the cornea seems to provide corneal xenografts with some degree of protection. 33 105 0.0165 0.0553 1000s 106 32.0% 59.2% *a is a scale factor, b represents the exponent of the nonlinear relationship between stress and strain.
†P is the value of G (t) at the end of the stress-relaxation test, K is the slope of fitted G (t)-In t line. Because the cornea is an avascular tissue, hyperacute rejection, which results from vascular occlusion and is commonly seen in vascularized solid organ xenografts, 34 has not been seen in corneal xenografts in either small or large animal models. 31, [35] [36] [37] [38] However, corneal endothelial cells seem to be highly susceptible to lysis by complement-fixing antibody 39, 40 because of the lack of complement regulatory proteins (CRP) on these cells. 41 Complement may also contribute to rejection through the antibody-independent alternative pathway. 42 
The Humoral Response
WT pig corneas express Gala1,3Gal (Gal), the major porcine antigen against which nonhuman primates and humans have preformed (natural) antibodies. [43] [44] [45] [46] [47] This is mostly confined to the anterior stromal keratocytes. 48, 49 Gal expression is gradually induced on corneal stroma and endothelial cells during in vitro culture and after pig-to-rat corneal Tx. 49 Binding of anti-Gal antibodies to pig cells in vitro results in rapid complement-mediated destruction of the cells. 50 In experimental organ xeno-Tx, this injury can be delayed by intensive immunosuppressive therapy, but this would not be an option with corneal grafts. If a corneal graft is placed into a high-risk patient, for example, with a neovascularized and inflamed host bed, preformed antipig antibodies, particularly anti-Gal antibodies, will gain immediate access to the graft and will almost certainly reduce graft survival. In the long term, therefore, the Tx of corneas from WT pigs is likely to be problematic, even under cover of topical steroids and/or systemic immunosuppression.
Clinical studies suggest that, in some instances, antibodies may contribute to corneal allograft failure if the recipient has been sensitized previously to donor alloantigens. Similarly, sensitization to xenoantigens has been detrimental to graft survival in rodent models of xeno-Tx. 35, 51 This is, at least in part, a byproduct of the T cell-mediated response generated to the graft. However, importantly, the current evidence, although limited, is that sensitization to pig antigens, for example, after pig corneal xeno-Tx, would not result in the generation of antipig antibodies that might cross-react with alloantigens and therefore prohibit subsequent corneal allo-Tx. 52 Similarly, sensitization to an allograft would not be detrimental to a subsequent pig xenograft. 52 Current advances in the genetic engineering of pigs have resulted in pigs that do not express the Gal epitope [a1,3-galactosyltransferase gene-knockout (GTKO) pigs]. 53, 54 The availability of these pigs will allow conclusions to be drawn with regard to the role of anti-Gal antibodies in the humoral rejection of the pig cornea. Preliminary data from our own laboratory indicate that the human humoral immune response to GTKO corneal cells is significantly weaker than to WT pig cells (Hara H, unpublished data, 2010) . Pigs also express other (non-Gal) antigens, against which there is a weaker antibody-dependent complement-mediated response. 50, 55 It is difficult to determine the nature of the non-Gal antigens that are present on pig corneas, although the presence of N-glycolylneuraminic acid is likely. 52, [56] [57] [58] [59] [60] The Cellular Response Immune-mediated destruction of corneal allografts and xenografts is primarily CD4 + T cell-mediated and targets the corneal endothelial cell. 32, 37, 61 CD8 + T cells and natural killer T cells may play a role in rejection when CD4 + T cells are absent or their function is impaired. 62 The immune response to corneal xenografts seems to occur almost exclusively by the indirect pathway, 63 that is, the conventional route for presentation of foreign antigen to T cells via host antigen-presenting cells. There is a resident myeloid corneal dendritic cell population that normally does not express major histocompatibility complex class II antigens but can readily upregulate class II expression during inflammation. 64 Thus, it is likely that a population of passenger leukocytes in xenogeneic corneas is involved in direct xenoantigen presentation to host T cells as takes place in the alloimmune response. 65 One of the costimulatory interactions occurs between CD28 (on the surface of T cells) and the B7 ligands, CD80 and CD86 (on antigen-presenting cells). Porcine endothelium, unlike human endothelium, constitutively expresses CD80 and CD86 and is fully capable of stimulating a human T cell-response through the direct pathway, providing the potential for full human T cell-activation at the donor endothelial cell surface. 66 In models of corneal allograft rejection, strong expression of the genes for interleukin (IL)-2 and interferon-g and low expression of genes for IL-4 and IL-10 have been described. 67, 68 This observation underlines the role of the Th1 response in corneal allograft rejection. However, abundant Th2 cytokine genes (IL-4 and IL-10) are expressed, in addition to expression of Th1 cytokine genes. 69 The rejection of xenogeneic corneal grafts seems to be mediated by proinflammatory cytokines, especially interferon-g, that are released by CD4 + and/or CD8 + T cells at the graft site. 33, 69 In addition to these cytokines, rejected xenografts are significantly associated with expression of the genes for inducible nitric oxide synthase (iNOS) and with nitric oxide (NO) production. The presence of iNOS and NO, the main effector molecules responsible for macrophage-mediated cytotoxicity, can be considered as indirect evidence for the role of macrophages in corneal xenograft rejection. Infiltration of macrophages in the graft and aqueous humor has been observed when the graft is rejected. 31 The role of macrophages in corneal allograft rejection has been well documented, 70 and depletion of macrophages at the time of corneal Tx prolongs graft survival. 71 It is likely that macrophages play a similar role in the rejection of xenografts. 31 In view of the humoral and cellular immune barriers, it is likely that successful corneal xeno-Tx will require the use of corneas from pigs with multiple genetic modifications (see below).
IMMUNE PRIVILEGE RELATING TO CORNEAL XENOGRAFTS
Immune privilege is well documented in relation to the eye, brain, ovary, testis, adrenal cortex, and certain solid tumors and in the fetus in pregnancy. 72 It is thought to be an evolutionary adaptation to protect vital structures from the potentially damaging effects of an inflammatory immune response. In the eye, the cornea, anterior chamber, vitreous cavity, and subretinal space are all considered to be immune-privileged sites.
The mechanisms that underlie immune privilege of corneas have been reviewed. 1, 3, 72, 73 They include an absence of blood vessels and lymphatics, weak expression of major histocompatibility complex antigens, expression of Fas ligand (FasL, CD95L) and programmed death ligand 1(PD-L1), 74, 75 few (immature) antigen-presenting cells, and the presence of immunomodulating molecules, such as IL-10, transforming growth factor b, and CRPs in the aqueous humor.
However, immune privilege of the cornea is relative. With the exception of patients with corneal dystrophies, such as keratoconus, most keratoplasty patients have corneal graft beds that have lost their immune privilege from previous inflammation, neovascularization, trauma, or infections. 2 This may predispose to rejection of a corneal allograft, 76 and this is likely to be even more so in the case of a corneal xenograft.
Of potential importance to xeno-Tx, levels of complement components in aqueous humor are less than those in serum, although they can be increased in the presence of inflammation. 41 Furthermore, several CRPs have been demonstrated to be expressed constitutively in the cornea, particularly in the epithelium, including decay-accelerating factor, C1 inhibitor, beta 1H, and C3b inhibitor. 41, 77 These CRPs protect autologous cells from complement-mediated injury. Unlike complement, some of these molecules are highly species specific. The absence of CRPs of the appropriate species on a corneal xenograft may thus act to augment complement-mediated damage and help to explain why antibody plays a more important role in corneal xenograft rejection than it does in allograft rejection.
Many of the complement pathway components have been shown to be present in tears, 78 aqueous humor, 77, 78 and cornea 42, 77 of normal humans. Strong expression of each of the CRPs, such as CD46, CD55, and CD59, has been demonstrated in human corneal epithelium but not in endothelium. The endothelium, therefore, might be a particular target for complement. Thus, graft injury by recipient complement is likely to occur unless recipient CRPs (eg, human) are expressed on xenograft cells. Pigs are now available that express one or more human CRPs. 50, [79] [80] [81] [82] [83] 
GENETIC ENGINEERING OF PIGS
There have been significant advances in recent years in the genetic engineering of pigs. It is now possible to knockout a gene and insert one or more genes. Pigs expressing a human CRP, such as decay-accelerating factor (CD55) 79 or membrane cofactor protein (CD46), 82 that provide considerable protection against primate complement-mediated injury, have been available through microinjection techniques for several years. 79 However, nuclear transfer/embryo transfer offers greater possibilities because the gene can be deleted or inserted at a specific site.
The first WT (unmanipulated) pig was cloned in 2000. 84 Pigs homozygous for GTKO were first produced in 2003. 53, 54 In these pigs, the gene for the enzyme, a1,3-galactosyltransferase, that produces the Gal saccharide-that is the major target for primate antipig antibodies-has been deleted. GTKO pigs, therefore, lack this major antigen.
Primate natural antibodies can also be directed to antigens other than Gal (non-Gal antigens), although the level of antibody directed toward these antigens is significantly less than that directed to Gal. 55, 85, 86 Anti-nonGAL antibodies can, however, result in rejection of a pig organ graft in a nonhuman primate. 87, 88 Because this rejection is mediated by complement, it can largely be prevented by the expression of a human CRP on GTKO pig cells. 50, 83 Several pigs with genetic modifications of relevance to xeno-Tx have been produced, for example, (1) GTKO pigs transgenic for CD46 50, 83 ; (2) GTKO pigs transgenic for the porcine costimulatory blockade agent, porcine cytotoxic T lymphocyte antigen 4-immunoglobulin (pCTLA4-Ig), 89 that provides local immunosuppression against the T cell-response (although these pigs produce so much CTLA4-Ig that they become immune incompetent, resulting in repeated infectious complications); (3) dominant-negative class II transactivator gene mutant pigs, in which upregulation of swine leukocyte antigen class II expression on vascular endothelial cells after activation is suppressed, thus protecting the cells from injury induced by primate CD4 + T cells 90 ; and (4) pigs expressing ''anticoagulant,'' ''antiinflammatory,'' and ''antiapoptotic'' genes, for example, tissue factor pathway inhibitor (Phelps C, personal communication), CD39 (d'Apice A, personal communication), thrombomodulin, 91,92 A20, 93 and hemoxygenase-1 (HO-1). 94, 95 Increasingly, therefore, pigs with multiple genetic modifications of relevance to xeno-Tx are becoming available. Our initial in vitro studies on corneal endothelial cells from GTKO/CD46 pigs are encouraging and will be reported fully elsewhere (Hara H, et al, unpublished data, 2010) ; in brief, they demonstrate a much greater resistance to the human humoral and cellular immune responses than WT pig corneal endothelial cells. It is not unduly optimistic to suggest that multiple manipulations will in the relatively near future provide pigs with corneas completely protected from the human innate and adaptive immune responses.
ANATOMICAL AND BIOMECHANICAL CONSIDERATIONS
Even if the immunological barriers can be overcome, the question arises of whether the structure and biomechanical parameters of the porcine cornea are sufficiently similar to those of the human cornea to provide an alternative source for Tx. In view of the difficulty of obtaining human corneas in sufficient numbers for studies of the mechanical properties of corneas, animal corneas have been investigated as potential models. Several of these studies have involved pig corneas and provide data of value in assessing the suitability of pig corneas for clinical xeno-Tx. [96] [97] [98] [99] [100] Pig corneal diameter, thickness, and refractive power have been compared with those of human corneas [9] [10] [11] (Table 3) . Because the mean pig corneal diameter is larger than that of humans, and in corneal Tx usually only the central 6-8 mm of the cornea is grafted, the diameter of the pig cornea is adequate. The pig cornea, although consisting of the same 5 basic layers as the primate cornea, is slightly thicker. The primate corneal epithelium is stratified into 5 cellular layers, whereas the pig corneal epithelium is slightly thicker, consisting of 7-9 cell layers 101 (Fig. 1) . The pig cornea has a Bowman layer similar to that in a human. 102, 103 The refractive power of the pig cornea is not different from that of a human cornea. 10 By testing freeze-thawinduced damage, Oh et al 104 demonstrated that pig corneal stroma was similar to that in the human.
Zeng et al 105 measured tensile strength, stress-strain relationship, and stress-relaxation properties in both human and porcine corneas ( Table 3 ). The tensile strength and stressstrain relation were very similar, but significant differences between human and pig tissues were observed in the stressrelaxation relationship. Porcine corneas relaxed much more than human corneas. However, this difference may be a function of the relative ages of the corneas tested or of the methods of storage. Two further studies shed some light on this possibility.
Ahearne et al 106 demonstrated that porcine corneas were physically weaker than human corneas and had a more linear loading-unloading cycle. However, they suspected that the storage conditions of the corneas influenced strength and that investigation into the influence of the storage media and conditions on the mechanical properties of the cornea might provide a better understanding of such physiochemicalmechanical interplays. Furthermore, when placed in a storage solution, porcine corneas seemed to swell more quickly than human corneas. Swelling reduced the strength of both corneas, but again the authors suggested that the storage media and conditions may play important roles in the rate of corneal swelling. They concluded that porcine corneas seemed to be less stiff and to demonstrate more linear response than human corneas under loading.
Elsheikh et al 107 concluded that human and porcine corneas had almost the same responses under short-term and long-term loading. They both exhibited nonlinear stress-strain behavior and reacted to sustained loading in a similar fashion. Although human corneas were significantly stiffer than porcine corneas, human corneas crept less under long-term loading and could sustain their stress state for longer compared to porcine corneas. In the authors' opinion, these differences cast doubt on the suitability of porcine corneas as models for human corneas in mechanical studies.
Under short-term inflation testing, both human and porcine corneas demonstrated hyperelastic behavior with an initial low stiffness and a final high stiffness. However, while human corneas experienced a nonlinear behavior with a gradually increasing stiffness, porcine corneas seemed to have more of a bilinear behavior with a distinct change in stiffness at about 10 mm Hg posterior pressure. Porcine corneas also seemed to have lower stiffness at all behavior stages compared with human corneas, although this could have been related to the relatively higher age of the human corneas tested.
In summary, this study suggested that porcine corneas seemed to be less able to maintain their initial shape or stress condition compared with human corneas. Porcine corneas deformed approximately twice as much as human corneas under ''creep'' testing. In stress-relaxation tests, the stress reductions experienced by porcine corneas were again almost twice than those observed in human corneas (Table 3) . 107 When human corneas were divided according to age, there was a gradual and significant stiffening with age under short-term loading, correlating with an earlier study by this group, 108 and a gradual reduction in both creep strain and stress-relaxation. The confirmed age-related short-term stiffening and the possible longterm stiffening could have contributed to the differences reported in this study between the relatively old human corneas and the young porcine corneas. In vivo experimental data are required to compare the biomechanical features of corneas from humans and pigs of similar ages.
There is not a large body of data supporting the idea that the stiffness properties of a cornea are essential for its visual function. The stiffness and flexibility of the cornea, limbus, and sclera differ from one another, suggesting that consistency of this property is not an essential factor in maintenance of the integrity of the globe. In summary, therefore, the evidence is that age-matched human and porcine corneas show sufficient similarity in biomechanical parameters to suggest that porcine corneas are likely to provide a successful alternative to human corneas in this respect.
Finally, considering strength, it is important to consider that the cornea itself is not the weakest component of the system. The porcine corneas are to be used in full-thickness keratoplasty, a procedure that weakens the eye. Several studies 109, 110 and anecdotal evidence from surgeons indicate that mechanical failure (globe rupture) of full-thickness grafts inevitably occurs at the suture line between the graft and the host. This failure most frequently occurs in the first months after Tx, but can occur decades later. The strength of the globe seems to be permanently compromised by keratoplasty. The relatively small difference between the strength of human and porcine corneas is certainly a factor to be considered, but the strength of the cornea from either source greatly exceeds the strength of the suture bond between the grafted and host tissue. Consequently, although consideration of the differences in biomechanical properties of the corneas is warranted, there seems little justification to exclude the use of pig corneas for clinical Tx based on their known differences in biomechanical properties.
CONCLUSIONS
Disease of the cornea is a major cause of blindness worldwide. The worldwide need for corneal Tx far exceeds the supply of deceased human donor corneas. Successful acceptance of pig corneas is more likely than for pig organ xenografts because of the lack of immediate revascularization, and thus an absence of hyperacute rejection. The results obtained from the Tx of corneas from WT pigs into nonhuman primates have been surprisingly good and encouraging. Considerable effort is currently being expended in developing genetically engineered pigs that should prove greatly preferable sources of corneas for clinical Tx. There seems to be no overwhelming biomechanical differences between pig and human corneas that might prohibit xeno-Tx. There is every reason for optimism that corneal xeno-Tx will become a clinical reality within the next few years.
